Hong Kong
· Delayed Price · Currency is HKD Sichuan Kelun-Biotech Biopharmaceutical Company Description
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
Its pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC.
The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist.
It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited.
The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
| Country | China |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,837 |
| CEO | Junyou Ge |
Contact Details
Address: No. 666 Xinhua Avenue Chengdu China | |
| Website | kelun-biotech.com |
Stock Details
| Ticker Symbol | 6990 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Junyou Ge | President, Chief Executive Officer, Chief Operating Officer, GM and Executive Director |
| Zejian Zhou | Chief Financial Officer and Joint Company Secretary |
| Yi Feng | Deputy GM, Chief Strategy Officer and Senior Vice President |
| Dr. Xiangyang Tan | Deputy GM and Chief Scientific Officer of Large Molecule |
| Dr. Xiaoping Jin | Deputy GM and Chief Medical Officer |
| Dr. Wensheng Yu | Chief Scientific Officer of Small Molecules |
| Ming Fai Chung C.P.A. | Joint Company Secretary |
| Wei Chen | Deputy General Manager |